MyDekla ( Daclatasvir)is specifically indicated for use with sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) of genotype 1, 3, or 4
The other medications used in combination include sofosbuvir, ribavirin, and interferon, vary depending on the virus type and whether the person has cirrhosis. MyDekla ( Daclatasvir) stops HCV viral RNA replication and protein translation by directly inhibiting HCV protein NS5A.
It is taken by mouth once a day. The recommended dose is 60 mg taken orally once daily with or without food in combination with sofosbuvir. The recommended treatment duration is 12 weeks. Dose modification: reduce dosage to 30 mg once daily with strong CYP3A inhibitors and increase dosage to 90 mg once daily with moderate CYP3A inducers.
Currently, there are no required dosage adjustments with concurrent use of daclatasvir and immunosuppressants, narcotic analgesics, antidepressants, sedatives, and cardiovascular agents.
Concurrent use with amiodarone, sofosbuvir and daclatasvir has may result in an increased risk for serious slowing of the heart rate. Common side effects with sofosubvir and daclatasvir include headache, feeling tired, and nausea.
With daclatasvir, sofusbivir, and ribavirin the most common side effects are headache, feeling tired, nausea, and red blood cell breakdown. It should not be used with St. John's wort, rifampin, or carbamazepine. It works by inhibiting the HCV protein NS5A. It is on the World Health Organization's List of Essential Medicines
Portion 'A' First Floor,
Old No. 131, New No. 50,
Pedariyar Koil Street,
Seven Wells, Chennai - 600001.